CDER Talks Switches, Monograph 'More Than Ever,' But Mum On Changes
This article was originally published in The Tan Sheet & The Rose Sheet
Officials from FDA's drug center describe their work on the Nonprescription Safe Use Regulatory Expansion initiative and on the center's evaluation of potential solutions to the OTC drug monograph process logjam. A CDER attorneys says FDA" is working towards finalizing" an NSURE regulatory framework.
You may also be interested in...
Industry has opposed establishing an intermediate class of drugs between Rx and OTC, and FDA has held it does not have authority to require firms to allow products to be approved for behind-the-counter access or some other alternative distribution. But the creation of some form of third route to access appears likely.
Three warnings during inspections, a warning letter and meeting with FDA officials didn’t stop Grandma’s Herbs from using drug claims. FTC reimburses consumers who bought three supplements deceptively marketed as treatments for pain and other health conditions related to aging.
J&J reported worldwide consumer health and personal care product Q3 sales up 4.1% to $3.7bn driven by 18.2% increase in OTC drug sales. Excluding OTC, its consumer business results would have been down as sales for all other sectors slipped.